Dublin, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The "Global Genomics Partnering Terms and Agreements 2015 to 2022" report has been added to ResearchAndMarkets.com's offering.
Access to 900+ Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual Genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of Genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Genomics dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Genomics deals since 2015. Deals are listed by headline value, signed by big pharma, most active Genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Genomics dealmaking with a brief summary followed by a comprehensive listing of Genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2015. The chapter is organized by specific Genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Genomics partnering company A-Z, deal type definitions and Genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genomics technologies and products.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Global Genomics Partnering Terms and Agreements 2015 to 2022 includes:
Trends in Genomics dealmaking in the biopharma industry since 2015
Access to headline, upfront, milestone and royalty data
Access to over 900 Genomics deal records and contract documents where available
The leading Genomics deals by value since 2015
Most active Genomics dealmakers since 2015
The leading Genomics partnering resources
In Global Genomics Partnering Terms and Agreements 2015 to 2022, the available contracts are listed by:
Stage of development at signing
Deal component type
Specific therapy and technology target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Genomics dealmaking
2.2. Genomics partnering over the years
2.3. Most active Genomics dealmakers
2.4. Genomics partnering by deal type
2.5. Genomics partnering by therapy area
2.6. Deal terms for Genomics partnering
2.6.1 Genomics partnering headline values
2.6.2 Genomics deal upfront payments
2.6.3 Genomics deal milestone payments
2.6.4 Genomics royalty rates
Chapter 3 - Leading Genomics deals
3.2. Top Genomics deals by value
Chapter 4 - Most active Genomics dealmakers
4.2. Most active Genomics dealmakers
4.3. Most active Genomics partnering company profiles
Chapter 5 - Genomics contracts dealmaking directory
5.2. Genomics contracts dealmaking directory
Chapter 6 - Genomics dealmaking by technology type
Appendix 1 - Genomics deals by company A-Z
Appendix 2 - Genomics deals by stage of development
Appendix 3 - Genomics deals by deal type
Appendix 4 - Genomics deals by therapy area
Appendix 5 - Deal type definitions
Appendix 6 - Further Reading
For more information about this report visit https://www.researchandmarkets.com/r/fqb8k5
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900